| NVSN Stock | | | MXN 2,004 134.33 6.28% |
CFO
Mr. Harry Kirsch was Chief Financial Officer and Member of the Executive Committee of Novartis Inc. since May 1, 2013. Mr. Kirsch joined Novartis in 2003 and, prior to his current position, served as CFO of the Companys Pharmaceuticals Division. Under his leadership, the divisions core operating income margin increased, in constant currencies, every quarter of 2011 and 2012 despite patent expirations. At Novartis, he also served as CFO of Pharma Europe, and as Head of Business Planning Analysis and Financial Operations for the Pharmaceuticals Division. Mr. Kirsch joined Novartis from Procter Gamble in the United States, where he was CFO of PGs global pharmaceutical business. Prior to that, he held finance positions in various categories of PGs consumer goods business, technical operations, and Global Business Services organization. Mr. Kirsch holds a diploma degree in industrial engineering and economics from the University of Karlsruhe in Germany. From 2015 to 2018, he represented Novartis on the board of GlaxoSmithKline Consumer Healthcare Holdings Ltd. since 2013.
| Age | 58 |
| Tenure | 11 years |
| Phone | 41 61 324 1111 |
| Web | https://www.novartis.com |
Novartis Management Efficiency
The company has return on total asset
(ROA) of
0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.1093 %, meaning that it generated $0.1093 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities.
Novartis AG has accumulated 20.24
B in total debt with debt to equity ratio
(D/E) of 0.67, which is about average as compared to similar companies. Novartis AG has a current ratio of 0.88, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Novartis until it has trouble settling it off, either with new capital or with free cash flow. So, Novartis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novartis AG sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novartis to invest in growth at high rates of return. When we think about Novartis' use of debt, we should always consider it together with cash and equity.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. NOVARTIS operates under Drug ManufacturersGeneral classification in Mexico and is traded on Mexico Stock Exchange. It employs 105794 people. Novartis AG (NVSN) is traded on Mexican Exchange in Mexico and employs 102,000 people.
Management Performance
Novartis AG Leadership Team
Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee | |
| Paul Penepent, Head Accounting | |
| Joerg Reinhardt, Independent Non-Executive Chairman of the Board | |
| Ton Buechner, Non-Executive Independent Director | |
| Robert PharmD, Chief Officer | |
| Karen Hale, Chief Officer | |
| Charles Sawyers, Non-Executive Independent Member of the Board | |
| Steven Baert, Chief People & Organization Officer, Member of the Executive Committee | |
| John Tsai, Head of Global Drug Development and Chief Medical Officer, Member of the Executive Committee | |
| Richard Saynor, Chief Executive Officer of Sandoz, Member of the Executive Committee | |
| Frans Houten, Non-Executive Independent Director | |
| Nancy Andrews, Non-Executive Independent Director | |
| Daniel Vasella, Honorary Chairman of the Board | |
| Susanne Schaffert, President of Novartis Oncology, Member of the Executive Committee | |
| Enrico Vanni, Lead Independent Non-Executive Vice Chairman of the Board | |
| Bertrand Bodson, Chief Digital Officer, Member of the Executive Committee | |
| Robert Weltevreden, Head of Novartis Business Services (NBS), Member of the Executive Committee | |
| Elizabeth Doherty, Non-Executive Independent Director | |
| Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee | |
| Alex Krauer, Honorary Chairman of the Board | |
| Patrice Bula, Non-Executive Independent Director | |
| Charlotte PamerWieser, Corporate Secretary | |
| Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel | |
| Andreas Planta, Non-Executive Independent Director | |
| William Winters, Non-Executive Independent Member of the Board | |
| Ann Fudge, Non-Executive Independent Director | |
| Srikant Datar, Non-Executive Independent Director | |
| MarieFrance Tschudin, President of Novartis Pharmaceuticals, Member of the Executive Committee | |
| Samir MD, Global Relations | |
| Simon Moroney, Non-Executive Independent Director | |
| James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee | |
| Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee | |
| Harry Kirsch, Chief Financial Officer, Member of the Executive Committee | |
| Bridgette Heller, Non-Executive Independent Director | |
Novartis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to
measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to
predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.